The 20th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) meeting took place as a virtual event on the 11-12 May 2022.
The 2022 IOTOD faculty led an engaging two-day meeting, featuring international field experts speaking on multiple and emerging topics, such as: the changing patient profile, opioid analgesic dependence, opioid substitution therapy, the experience so far with long-acting buprenorphine formulations from the patients’ perspectives, and optimising best approaches to address viral hepatitis in PWIDs.
Highlights report – Session 5: Viral hepatitis: uncovering the unknown
Faculty
The IOTOD conference partners with internationally-renowned faculty from a variety of backgrounds and specialities.
Director and Senior Staff Specialist Hunter New England Local Health District Drug & Alcohol Clinical Services Newcastle NSW, Australia Head of the Department of Addictions, University Hospital of Grenoble Grenoble, France Consultant Psychiatrist; and Honorary Professor of the Faculty of Medical and Human Sciences, University of Manchester Manchester, UK Professor of Addiction Psychology, Addictions Department, King’s College London London, UK Drug and Alcohol Services, South-East Sydney Local Health District Sydney, Australia Head Of School School of Social Work and Social Policy University of Strathclyde Glasgow, Scotland Professor of Hepatology, Queen Mary's University of London & Consultant, Bart's Health NHS Trust London, UK Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, and Professor of Practice (Viral Hepatitis), Imperial College London London, UK The 2022 IOTOD conference is supported by the following companies: Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Accord Healthcare is a dynamic pharmaceutical company, spanning both generics and speciality products, committed to addressing public health priorities. We are now bringing our expertise and patient-centric approach to address some of the ties related to addiction management. At Accord Healthcare, we are sensitive to the diverse pasts and journeys of people living with addiction, as well as the related social stigmas, which can become barriers to recovery. We understand the challenges and complexities faced by the healthcare community in the support and treatment of patients with addiction Molteni Farmaceutici is a privately held pharmaceutical company founded in 1892 with a strong knowledge and experience in opioids and a wide spectrum of pharmaceutical products for the treatment of pain and drug addiction. Molteni Farmaceutici is committed to consolidate its international leadership, always focused on the main therapeutic areas, enlarging its geographies, to satisfy patients ‘needs and improve the standard of care. With an eye to development and internationalization, Molteni Farmaceutici constantly pursues chemical-pharmaceutical, clinical and biomedical research to develop new drugs and improve therapeutic applications. OUR VISION Molteni Farmaceutici constantly focuses its attention on people and society, without losing sight of numbers and markets. A solid past behind it, the awareness of its own value and the ability to look to the future with determination, make the company an Italian, Tuscan, and Florentine excellence in the increasingly global drug market. OUR MISSION Molteni Farmaceutici at the centre of its work and commitment always puts the person, his health, and his quality of life. The company, aware and proud of its responsibility, continues to seek and pursue an ever higher therapeutic standard, with ongoing innovation and research. Indivior is a global pharmaceutical company working to change patients’ lives by developing medicines to treat addiction and serious mental illnesses.
Professor Adrian Dunlop
Maurice Dematteis
Professor Oscar D’Agnone
John Marsden
Nicholas Lintzeris
Professor Trish Hafford-Letchfield
Graham Foster
Ashley Brown
Sponsors
Camurus
Gilead
Accord Healthcare
Molteni Farmaceutici
Indivior
The medications Indivior provides play an essential role in treating opioid use disorder and addressing the opioid crisis.
Patient needs inspire us.
At the heart of Indivior is an unwavering commitment to support the patient journey to treatment and recovery, enable access to effective treatment, and provide education, new scientific understanding, and knowledge to the treatment community.
From the beginning, we have worked hard to destigmatize opioid use disorder by advocating that opioid use disorder to be recognized as a treatable medical condition, and not a moral failing.
We have an unrivaled track record for developing innovative medicines to treat opioid addiction.
Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
The IOTOD experience
Measuring behavioural changes
2011 marked the year measurement of delegate behavioural changes began. These measurements showed the IOTOD conference elicited measurable significant improvements in physician behaviours over the years, which have been published in the European Journal of CME.